No Data
No Data
No Data
Global Transdermal Medical Patch Market Analysis 2024-2029, Featuring Novartis, Viatris, Nitto Denko, Luye Pharma, Hisamitsu Pharmaceutical, Medline Industries, Corium, UCB, Teikoku Pharma and More
DUBLIN, March 25, 2024 /PRNewswire/ -- The "Global Transdermal Medical Patch Market: Analysis By Type, By Application, By Distribution Channel, By Region Size & Forecast to 2029" report has been adde
Luye Pharma Grants Myung In Pharm Exclusive Rights to Commercialize Rivastigmine Twice Weekly Transdermal Patch in South Korea
Luye Pharma's Schizophrenia Injectable Surpasses Patent Challenges in US; Shares Fall 3%
Luye Pharma Group's (HKG:2186) LY03010 injectable for schizophrenia and schizoaffective disorder overcame patent challenges during the new drug application review process by the US Food and Drug Admin
Luye Pharma's Small Cell Lung Cancer Treatment Secures Hong Kong Marketing Approval
Hong Kong's pharmacy and poisons board approved Luye Pharma's (HKG:2186) marketing application for lurbinectedin intended to treat metastatic small cell lung cancer, a Wednesday filing said. Mainland
Schizoaffective Disorder Drug Pipeline Research Report 2023 Featuring Lyndra Therapeutics, Luye Pharma Group, BioXcel Therapeutics, & Reviva Pharma - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Schizoaffective Disorder - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.The "Schizoaffective Disorder - Pipeline Insight, 2
Luye Pharma Files New Drug Application in US for Schizophrenia Medication
Luye Pharma Group (HKG:2186) submitted a new drug application to the US Food and Drug Administration for LY03010 as a treatment for schizophrenia and schizoaffective disorder. LY03010 "is expected to
No Data